AXIOS™ for Gallbladder Drainage as an Alternative to Percutaneous Drainage IDE



Status:Not yet recruiting
Conditions:Gastrointestinal, Gastrointestinal, Gastrointestinal
Therapuetic Areas:Gastroenterology
Healthy:No
Age Range:18 - Any
Updated:12/9/2018
Start Date:March 2019
End Date:January 2021
Contact:Evelyne Ho
Email:Evelyne.Ho@bsci.com
Phone:(508) 683-4140

Use our guide to learn which trials are right for you!

A Multicenter, Prospective Study of EUS-Guided Transluminal Gallbladder Drainage in Patients With Acute Cholecystitis as an Alternative to Percutaneous Gallbladder Drainage

To evaluate the safety and effectiveness of the AXIOS™ Stent with Electrocautery Enhanced
Delivery System in the management of symptoms of acute cholecystitis as an alternative to
percutaneous gallbladder drainage.

This study is a prospective, single arm, multi center trial. Treatment of up to 30 patients
will take place at up to 7 clinical centers. Patients who meet all eligibility criteria will
receive the AXIOS stent for up to 60 days indwell and 72 hour follow-up after stent removal.

Inclusion Criteria:

1. Patient requiring intervention for the management of symptoms associated with acute
cholecystitis

2. Patients referred for percutaneous drainage of the gallbladder who are not surgical
candidates because of advanced age, anesthetic risk, significant co-morbidities and/or
overall health

3. Eligible for endoscopic intervention

4. Acute Cholecystitis (AC) Grade I (mild) or II (moderate) per Tokyo guidelines [3]:

- AC Grade I (mild) defined as acute cholecystitis in an otherwise healthy patient
with mild local inflammatory changes and without organ dysfunction. Criteria for
grade II or III not met.

- AC Grade II (moderate) defined by any one of the following characteristics

- Leukocytosis (>18,000 cells per mm3)

- Palpable, tender mass in right upper quadrant

- Symptom duration >72 hours

- Marked local inflammation (gangrenous or emphysematous cholecystitis,
pericholecystic or hepatic abscess, biliary peritonitis)

5. Pre-drainage imaging confirms sufficient stone-free space to allow AXIOS™ stent
deployment and complete flange expansion

6. 18 years of age or older

7. Willing and able to comply with the study procedures and provide written informed
consent form (ICF) to participate in the study

Exclusion Criteria:

1. AC Grade III (severe) per Tokyo guidelines defined by organ dysfunction in any one of
the following systems:

- Cardiovascular - Hypotension requiring administration of ≥5μg/kg/min of dopamine
or any dose of norepinephrine

- Neurologic - decreased level of consciousness

- Respiratory - PaO2/FiO2 <300

- Renal - Oliguria and Creatinine >2.0 mg/dl (>177 μmol/liter)

- Hepatic - International normalized ratio >1.5

- Hematologic - Platelet count <100,000/mm3

2. Obvious signs on diagnostic imaging of perforated, extensive gangrenous or ischemic
gallbladder

3. Hepatic abscess

4. Ascites

5. Advanced liver disease

6. Subjects with abnormal coagulation or who require ongoing complete anticoagulation

7. Bleeding diathesis

8. Altered anatomy of the upper gastrointestinal tract due to surgery of the esophagus,
stomach and duodenum that might preclude endoscopic drainage

9. Prior surgical, interventional radiology or endoscopic procedures for the treatment of
acute cholecystitis

10. Distance between gallbladder wall and duodenal or gastric wall > 1cm by US
(ultrasound) at the time of drainage

11. Patients with intervening gastric varices or vessels within a one centimeter radius of
the device insertion location

12. Patients that have allergies or are sensitive to any of the device materials

13. Patients with contraindications to use of electrical devices

14. Pregnancy

15. Prisoners and other vulnerable populations
We found this trial at
5
sites
Seattle, Washington 98101
(888) 862-2737
Principal Investigator: Shayan Irani, MD
Phone: 206-223-2319
Virginia Mason Medical Center Established in 1920, Virginia Mason began as an 80-bed hospital with...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
1648 Pierce Dr NE
Atlanta, Georgia 30322
(404) 727-5640
Principal Investigator: Field F Willingham, MD
Emory University School of Medicine Emory University School of Medicine has 2,359 full- and part-time...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
13001 E. 17th Pl
Aurora, Colorado 80045
303-724-5000
Principal Investigator: Raj Shah
Phone: (720) 848-2786
University of Colorado Denver The University of Colorado Denver | Anschutz Medical Campus provides a...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
Fort Wayne, Indiana 46845
Principal Investigator: Neil Sharma, MD
Phone: 260-266-1017
?
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Leuven, 3001
Principal Investigator: Schalk W van der Merwe, MD
Phone: 32 16 34 42 99
?
mi
from
Leuven,
Click here to add this to my saved trials